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Interleukin-33 (IL-33) is associated with several important immune-mediated disorders.
However, its role in uveitis, an important eye inflammatory disease, is unknown. Here,
we investigated the function of IL-33 in the development of experimental autoimmune
uveitis (EAU). IL-33 and IL-33 receptor (ST2) were expressed in murine retinal pigment
epithelial (RPE) cells in culture, and IL-33 increased the expression of Il33 and Mcp1
mRNA in RPE cells. In situ, IL-33 was highly expressed in the inner nuclear cells of
the retina of naı¨ve mice, and its expression was elevated in EAU mice. ST2-deficient
mice developed exacerbated EAU compared with WT mice, and administration of
IL-33 to WT mice significantly reduced EAU severity. The attenuated EAU in IL-33-treated
mice was accompanied by decreased frequency of IFN-γ+ and IL-17+ CD4+ T cells and
reduced IFN-γ and IL-17 production but with increased frequency of IL-5+ and IL-4+ CD4
T cells and IL-5 production in the draining lymph node and spleen. Macrophages from
the IL-33-treated mice show a significantly higher polarization toward an alternatively
activated macrophage phenotype. Our results therefore demonstrate that the endogenous
IL-33/ST2 pathway plays an important role in EAU, and suggest that IL-33 represents a
potential option for treatment of uveitis.
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Introduction
Uveitis, particularly posterior uveitis, is a sight-threatening
intraocular inflammatory disease, it can occur in isolation
or associated with other systemic immunological diseases
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such as Vogt–Koyanagi–Harada disease and Behc¸et’s disease.
Experimental autoimmune uveitis (EAU) in the mouse closely
resembles the pathology of human posterior intraocular inflam-
matory conditions such as sympathetic ophthalmia, sarcoidosis,
and birdshot retinochoroidopathy [1, 2]. The pathology of EAU is
mediated by autoantigen-specific CD4+ T cells whose activation
is accompanied by the infiltration of tissue damaging leukocytes,
such as macrophages and neutrophils, into the retina/choroid [3].
Both Th1 and Th17 cells are thought to be responsible for the
disease [4] while Th2 and regulatory T cells can protect against
EAU [5]. Previously, we have reported different phenotypes of
macrophages in the retina tissues during disease progression
from peak to later stages of EAU [6]. While some macrophages,
e.g. sialoadhesin positive macrophages, can exacerbate the inflam-
matory response in EAU [3], other types of macrophages are asso-
ciated with suppression of the disease [3, 7]. Here, we have inves-
tigated the role of IL-33 [8], the recently identified type 2 cytokine,
in EAU and the effect of IL-33 on the phenotypic changes of T cells
and macrophages during the disease development.
IL-33 is a member of the IL-1 cytokine family, which also
includes IL-1α, IL-1β, IL-18, and IL-1Ra. Different from IL-1 and
IL-18, full length IL-33 is bioactive and is released through cell
necrosis [9] or via vesicles in endothelial cells and fibroblasts [10].
IL-33 signals via the heterodimeric receptor consisting of ST2 and
IL-1R accessory protein [11]. The membrane form of ST2, encoded
by the ST2 gene [12], is expressed on cells including activated
Th2 cells [13] and mast cells [14]. ST2 is alternatively spliced to
produce a soluble form (sST2), which acts as a decoy receptor of
IL-33 [15]. Human IL-33 was detected in epithelial cells, fibrob-
lasts [8], and endothelial cells of inflamed tissues from patients
with rheumatoid arthritis and Crohn’s disease [16]. In rodents,
Il33 mRNA was detected in various tissues and organs including
lungs, lymph nodes, spleens, and the CNS [8]. IL-33 has pleiotropic
effects on immune responses [17] and plays an important role in
the development of many immune-mediated diseases. Previous
studies using in vivo disease models have shown that IL-33 exac-
erbates allergic inflammation [18] but confers resistance to par-
asite infection [19] and attenuates atherosclerosis [20] through
inducing type 2 immune responses. However, IL-33 is also able to
induce inflammatory hypernociception [21] and is a proinflamma-
tory cytokine in both antigen- and autoantibody-induced arthritis
via activating mast cells [17, 22, 23]. Recent studies show that the
IL-33/ST2 pathway plays a significant role in the amplification of
alternatively activated macrophage (M2) polarization. M2 appears
to play a key role in IL-33-mediated exacerbation of airway inflam-
mation [24], protection against obesity-related metabolic events
[25], and attenuation of EAE [26].
IL-33 has been detected in normal conjunctivae and human
vascular endothelial cells of giant papillae formations in allergic
conjunctiva [27]. However, the role of IL-33 in the development of
retinal inflammatory diseases is hitherto unknown. In the present
study, we show that IL-33 protein is highly expressed in retinal
cells, and the expression is markedly upregulated in EAU mice.
Furthermore, we found that ST2-deficient (ST2−/−) mice devel-
oped more severe retinal inflammation compared with WT mice,
while treatment of IRBP1–20-immunized mice with recombinant
IL-33 significantly attenuated the severity of EAU. The reduced
retinal inflammation of IL-33-treated mice was associated with
decreased frequency of IFN-γ+ and IL-17+, but increased IL-5+
and IL-4+ CD4 T cells in the draining lymph node (DLN) and
spleen. In addition, macrophages from the IL-33-treated EAU mice
showed greater polarization toward the M2 phenotype. Together
our results demonstrate that IL-33 is an endogenous regulator of
retinal inflammatory disease and suggest that IL-33 may be a novel
therapeutic agent for uveitis.
Results
Expression and function of IL-33 in the RPE cells
It is well documented that many epithelial cells in tissues express
IL-33 [8]. Retinal pigment epithelial (RPE) cells are an important
component of the blood retina barrier, which is central to retinal
homeostasis and involved in the development of many retinal dis-
eases. We first examined the expression of IL-33 in an established
murine RPE cell line [28]. Cells cultured in cell chamber slides
were used for immunohistochemical staining and cells cultured in
flasks were harvested for flow cytometry analysis. Our data show
that RPE cells expressed high levels of IL-33 as well as its recep-
tor ST2 (Fig. 1A and B). Furthermore, IL-33-activated RPE cells
showed increased expression of Il33 (Fig. 1C) and Mcp1 (Fig. 1D)
mRNA in an IL-33 dose-dependent manner although the effect
of IL-33 was not as profound as LPS stimulation. These results
demonstrate that IL-33 can amplify its own synthesis by the RPE
cells, and suggest that IL-33 may have important roles in retinal
homeostasis and disease development.
IL-33 expression in naı¨ve and EAU eye tissues
To identify the expression of IL-33 in vivo, we next examined the
expression of IL-33 in the normal eye tissues as well as tissues
from EAU mice. EAU was induced as described in “Materials and
methods.” IL-33 was expressed by cells in the inner nuclear layer
(INL) of retina tissues from na¨ıve C57BL/6 mice (Fig. 2A and B).
Because of the dark pigment in the RPE cells and in the choroid
in C57BL/6 mice, we used fluorescence immunohistochemical
staining to study the expression of IL-33 in the retina of both
C57BL/6 and BALB/c mice. Data in Figure 2C and D confirmed
IL-33 expression in INL cells in the retina of both strains of mice.
Interestingly, IL-33 expression levels in the RPE cells were strain
dependent, while RPE cells in C57BL/6 mice expressed low levels
of IL-33 (Fig. 2C and E), the expression was higher in the RPE
cells of nonpigmented BALB/c mice (Fig. 2D and F). In the retina
tissue from EAU mice (day 16 postimmunization) of the C57BL/6
background, the expression of IL-33 was markedly increased in
the INL with an increased number of IL-33 positive cells, and
these cells moved toward the outer nuclear layer (Fig. 2G–I). Sim-
ilar levels of IL-33 expression were also observed in eye tissues
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Figure 1. Expression and function of IL-33 on a murine
RPE cell line. (A) Immunohistochemical staining showing
expression of IL-33 on murine RPE cells, original magni-
fication ×100. (B) Expression of IL-33 and ST2 on murine
RPE cells shown by flow cytometry. (C and D) Il33 and Mcp-
1 mRNA expression by RPE cells analyzed by qPCR. Data
are shown as mean + SEM of three samples from a single
experiment. Data are representative of three independent
experiments. *p < 0.05, **p < 0.01, ***p < 0.001, compared to
medium alone as determined by Student’s t-test.
harvested at day 21 after immunization. These results indicate
that the expression of IL-33 is closely associated with EAU.
Recombinant IL-33 treatment attenuate EAU
development
To directly assess the role of IL-33 in EAU development, we
administered recombinant IL-33 i.p. to IRBP-immunized mice as
described in the “Material and methods.” On day 18 after immu-
nization, PBS-treated control mice developed retinal inflammation
with swelling of the optic disc, diffuse whitish retinal exudates in
the retina, and signs of vessel inflammation (vasculitis) (Fig. 3A).
In contrast, the retina of the IL-33-treated mice had significantly
less inflammation (Fig. 3B). IL-33-treated mice showed a signifi-
cant reduction in the clinical score compared to the control PBS-
treated mice (Fig. 3C). The clinical findings were confirmed by
histological examination of the eyes 25 days after immunization.
Vasculitis and marked cell infiltration in the retina were observed
in the retina of PBS-treated mice (Fig. 3D), while minimal evi-
dence of inflammation was seen in IL-33-treated mice (Fig. 3E).
IL-33-treated EAU mice developed significantly less retinal inflam-
mation with reduced pathological scores (Fig. 3F). Together, these
results demonstrate a significant beneficial effect of IL-33 in EAU.
ST2−/− mice develop exacerbated EAU
To identify an endogenous role of IL-33 in EAU, we next inves-
tigated the development of retinal inflammation in ST2−/− mice.
WT and ST2−/− mice of the C57BL/6 background were immu-
nized and then treated with PBS or IL-33 as above. Retinal
inflammation was evaluated on day 20 after immunization using
the fundus imaging system. As expected, WT mice developed optic
disc swelling with diffuse and localized inflammation in the retina
(Fig. 4A, upper left panel). The disease was markedly more severe
in the ST2−/− mice than in the WT mice. ST2−/− mice devel-
oped inflammation in the optic disc and surrounding retina, with
vessels covered by inflammatory infiltrates and vessels in the optic
disc barely visible (Fig. 4A, lower left panel). Furthermore, while
IL-33 treatment ameliorated the inflammation in the WT mice,
IL-33 had no significant effect in the ST2−/− mice (Fig. 4A, right
panels). The corresponding clinical scores of the four groups of
mice are shown in Figure 4B. The clinical observation was further
confirmed by histological analysis of the eye tissues on day 22
after immunization (Fig. 4C and D). While infiltrating cells and
vasculitis were seen in the retina of the control WT mice, minimal
inflammation was observed in the retina tissue of IL-33-treated
WT mice. In the ST2−/− mice, there was severe inflammation
in the retina and choroid with retinal detachment, local folds,
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Figure 2. Expression of IL-33 in retinal tissues of naı¨ve and EAU mice. (A) Isotype control staining in mouse retina; GL, ganglion cell layer;
INL, inner nuclear layer; ONL, outer nuclear layer; Ch, choroid. (B) Immunohistochemical staining of IL-33 (AMEC, red) in the retina of naı¨ve
C57BL/6 mice, arrows indicate IL-33-positive cells. (C–F) Immunofluorescence staining of IL-33 expression (TRITC, red) in naı¨ve retina of (C and
E) C57BL/6 and (D and F) BALB/c mice, arrows in (E) and (F) indicate expression of IL-33 in RPE cells. (G) Immunohistochemical (DAB, brown)
and (H) immunofluorescence (TRITC, red) staining of IL-33 expression in EAU retina tissues of C57BL/6 mice, arrows indicate IL-33-positive
cells. Retinal images are representative of at least four mice per group. (I) Number of IL-33+ cells in each view field with 600× magnification of
immunofluorescence-stained retina of naı¨ve and EAU C57BL/6 mice was enumerated and shown as mean + SEM (n = 4 samples) and are pooled
from two independent experiments. *p < 0.05, Student’s t-test. Scale bars in the figures indicate 100 µm.
and massive infiltration. The disease in the ST2−/− mice was
not attenuated by treatment with IL-33 (Fig. 4D). These results
therefore demonstrate an endogenous role of IL-33 in protecting
mice against uveitis.
IL-33 alters the cytokine production profile of
leukocytes in EAU mice
To investigate the immunological mechanisms underpinning the
role of IL-33 in EAU, we examined the cytokine production by
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Figure 3. IL-33 attenuates EAU disease. C57BL/6 mice were immunized for EAU and injected i.p. with (0.5 µg/100 µL) IL-33 or 100 µL PBS every
other day from day 9 to 25 postimmunization. Mice were examined for retinal inflammation using the fundus imaging system on day 18. (A and B)
Representative images of retinal inflammation in (A) PBS or (B) IL-33-treated mice, arrows in (A) indicate vasculitis and exudates. (C) EAU clinical
score of mice treated with PBS or IL-33. Mice were culled and eyes harvested on day 25 for histological examination. (D and E) Representative H&E
staining images of retina of (D) PBS- or (E) IL-33-treated mice, arrows show infiltrating cells. Ch, choroid; Re, retina. (F) EAU pathological score of
control and IL-33-treated mice. (C and F) Each symbol represents an individual mouse and bar indicates average score of EAU with n = 12 or 13 in
each group. Data are representative of three independent experiments. *p < 0.05 as determined by Mann–Whitney test.
the DLN and spleen cells ex vivo. WT C57BL/6 mice were immu-
nized and treated with IL-33 or PBS. Spleen and DLN cells were
harvested on day 21 and single-cell suspensions were cultured
with IRBP1–20 peptide. Supernatants were collected 72 h later and
examined for cytokine production by ELISA. DLN cells from IL-33-
treated EAU mice produced significantly less IFN-γ and IL-17 but
more IL-5 compared to the cells from PBS-treated control mice
(Fig. 5A). Consistent with the cytokine data, there was also a sig-
nificant reduction in the frequency of CD4+IL-17+, CD4+IFN-γ+,
and CD4+IL-17+IFN-γ+ cells, but an increase in the percentage
of CD4+IL-4+, CD4+IL-5+, and CD4+IL-4+IL-5+ T cells in the
DLN (Fig. 5B). Similar data were also observed in the spleen
tissues (data not shown). Interestingly, IL-33 treatment did not
lead to an increase in the frequency of CD25+ FoxP3+ regula-
tory T-cell population (data not shown). These results therefore
demonstrate that IL-33 significantly switched a Th1 and Th17
response to the Th2 phenotype during EAU development. To
further investigate whether T cells from IL-33-treated mice are
able to suppress EAU-associated inflammation, we purified CD4+
T cells from PBS or IL-33-treated mice and co-cultured them with
spenocytes from EAU mice in the presence of IRBP1–20 peptide.
T-cell from IL-33-treated mice, but not PBS-treated mice, signifi-
cantly suppressed IL-17 production by the spleen cells from EAU
mice (Fig. 5C).
IL-33 treatment increases MR+PDL2+ M2 macrophage
populations
Because of the well-defined role of IL-33 in macrophage polar-
ization toward an M2 phenotype [29], and the potential pro-
tective role of M2 in tissue inflammation [30], we analyzed
the macrophage phenotype in EAU mice with or without IL-33
treatment. WT C57BL/6 mice were immunized and treated with
IL-33 or PBS as above and single-cell suspensions were prepared
from the spleen and DLN tissues of mice 21 day after immuniza-
tion. Cells were then stained for cell surface F4/80 (macrophage),
CD206 (MR, mannose receptor) and CD273 (PD-L2), two
markers closely identified with M2 [31]. Macrophages from
IL-33-treated mice had significantly increased frequency of
PD-L2+ and MR+/PD-L2+ cells in the LN and the spleen compared
to that of the control PBS-treated mice (Fig. 5D). These results
therefore indicate that IL-33 treatment facilitates the polarization
of M2, which may additionally account for the IL-33-mediated
reduction of retina inflammation in EAU.
Discussion
Data presented here demonstrate that IL-33 has a protective effect
on intraocular inflammation in EAU. In mice lacking the IL-33
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Figure 4. ST2−/− mice developed exac-
erbated EAU. WT and ST2−/− mice were
immunized with 300 mg IRBP peptide1–20
and treated with PBS or IL-33 as in
Figure 3. Mice were examined for retinal
inflammation clinically on day 20 and eye
tissues examined for histological changes
on day 22. (A) Retinal inflammation
was examined using the fundus imaging
system. Arrows indicate exudates and
vasculitis in the retina. (B) EAU clinical
scores of WT and ST2−/− mice treated
with PBS or IL-33. (C) Histological exami-
nation of the eye tissues stained with H&E
staining, arrows indicate retinal detach-
ment and infiltrating cells in retina (gran-
uloma formation), arrowhead indicates
vasculitis. (D) EAU pathological scores in
WT and ST2−/− mice. *p < 0.05 as deter-
mined by Student’s t-test. Each symbol
represents an individual mouse and bar
indicates average score of EAU in each
group (n = 5–7 mice) from a single experi-
ment, which is representative of two inde-
pendent experiments.
receptor ST2, EAU was more severe while treatment of mice with
IL-33 attenuated disease severity in WT mice but not in the ST2−/−
mice. The protective effect of IL-33 in EAU was associated with
a shift of immune responses toward type 2 immune responses as
demonstrated by the increased frequency of Th2 cells and M2 in
the lymphoid organs.
IL-33 is constitutively expressed in normal epithelial and
endothelial cells in tissues such as human colon, lung, liver, and
skin [8, 16], as well as in human vascular endothelial cells in
allergic papillary conjunctivitis [32]. We show here the presence of
IL-33 and ST2 in cultured RPE cells and demonstrated an autocrine
upregulation of IL-33 in these cells. Many RPE-derived molecules
are known to be involved in local immune privilege in the eye
[33]; our findings here suggest that IL-33 may also be a key
immune-regulatory mediator in this context. LPS induced signifi-
cantly higher expression of both Il33 and Mcp1 mRNA suggesting
that the induction of EAU with CFA may well be a competitive
balance between pro- and anti-inflammatory signals of innate
immunity. We also found that the levels of IL-33 expression in the
RPE cells in retina tissues vary in different strains of mice. While
IL-33 is highly expressed by the RPE cells in the na¨ıve BALB/c
mice, the expression level was low in these cells in the na¨ıve
C57BL/6 background mice. This observation is consistent with a
protective role of IL-33 in retinal inflammation as BALB/c mice are
resistant whereas C57BL/6 mice are susceptible to EAU [34, 35].
Further immunohistochemical staining in the retina of na¨ıve mice
shows that that IL-33 was also constitutively expressed by cells
in the INL of retina, suggesting IL-33 may have eye-specific func-
tions under homeostasis and disease conditions. Our data of IL-33
staining in the INL also agree with a recent report that used an
IL-33-LacZ gene trap reporter [36]. The author further suggested
that the IL-33-positive cells are likely to be Muller glial cells. Since
microglia cells also exist in the INL of retina, it would be inter-
esting to confirm whether they also express IL-33 in the retina
tissues. IL-33 expression in the retina was elevated with increased
numbers of IL-33+ cells moved toward the outer nuclear layer
during EAU. These data indicate that IL-33 is closely associated
with the posterior inflammation of the eye, and hence might con-
tribute to its immune regulatory role in ocular inflammation. The
elevated expression of IL-33 in the retina of EAU mice may rep-
resent a failed attempt by the mice to contain EAU, which can be
effectively ameliorated with additional exogenously administered
recombinant IL-33.
IL-33 plays an important role in many inflammatory diseases
but its effect is model- and disease-specific [17]. While IL-33
exacerbates autoimmune collagen-induced arthritis via mast cell
degranulation [22], it also promotes type 2 immune responses
with the production of high levels of IL-5 and IL-13 [20] and drives
M2 macrophage differentiation thus protecting mice from EAE
[26] and atherosclerosis [20]. However, by doing so, IL-33 con-
tributes to the pathogenesis of asthma, atopic dermatitis, and aller-
gic conjunctivitis [18, 27]. Data reported here suggest that IL-33
is protective against retinal inflammation, and the effect is likely
to be endogenous as ST2−/− mice developed more severe EAU.
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Figure 5. Cytokine production and cell phenotype in the lymphoid organs of EAU mice treated with IL-33. C57BL/6 mice were treated with IL-33
or PBS as in Figure 3, and their DLNs and spleens collected on day 20 after immunization. (A) DLN cells were cultured with or without 50 µg/mL
IRBP1–20 for 72 h and the concentrations of IFN-γ, IL-17, and IL-5 in the supernatant determined by ELISA. Data are shown as mean + SEM of pooled
samples from five mice in each group from a single experiment, and are representative of three independent experiments. *p < 0.05, ***p < 0.001
compared to PBS-treated controls as determined by Student’s t-test. (B) DLN cells from a pool of five mice per group were stained for intracellular
cytokines. CD4+ cells were gated and analyzed for IL-17/IFN-γ or IL-4/IL-5 expression by flow cytometry. Data shown are representative of two
experiments. (C) T cells purified from PBS or IL-33-treated mice were co-cultured with splenocytes of day 18 EAU mice in the presence of IRBP
peptide1–20, and the concentration of IL-17 was determined by ELISA. Data are mean + SEM from four samples pooled from five mice in each group
from a single experiment. *p < 0.05, **p < 0.01 compared to PBS control and EAU group as determined by Student’s t-test. (D) F4/80+-gated DLN and
spleen cells from PBS- or IL-33-treated mice were stained with anti-PD-L2 and anti-MR antibodies. Percentage of PD-L2+ or MR+/PD-L2+ double
positive macrophages in the tissues was analyzed. Data are shown as mean + SEM with n = 7 from a single experiment, and are representative of
two independent experiments. *p < 0.05, **p < 0.01 compared to PBS controls as determined by Student’s t-test.
Although the relative importance of Th1 and Th17 cells in
the development of autoimmunity is still debated, the current
view suggests a more complex relationship between the two cell
subsets; they have overlapping and differential roles [1] in the
pathogenesis of EAU and other autoimmune diseases such as
EAE [37]. Classically activated macrophages are often involved in
tissue damage during early and peak stages of inflammatory dis-
eases, while regulatory M2 macrophages that appear in late stages
can significantly limit the damage [29, 30, 38]. It is generally
agreed that a shift in T-cell and cytokine profile toward a type 2
phenotype and the emergence of regulatory T cells [39–41] are
responsible for disease protection in EAE and EAU [5, 42]. While
we did not observe an apparent increase of FoxP3+ Treg cell pop-
ulation in the lymphoid organs of IL-33-treated mice, it is likely
that IL-33 reduces retinal inflammation via the reduction of Th1
and Th17 cells and skewing the immune response toward nonin-
flammatory, protective type 2 responses. As IL-33 is also important
in activating antigen presenting cells [43, 44] or innate lymphoid
cells [45] to induce Th2 type responses, it may have attenuated the
severity of EAU through inhibiting both the innate and the adap-
tive immune responses, e.g. switching the phenotype of anti-
gen presenting DCs and macrophages in the peripheral lymphoid
organs, and the microglia cells in the target retina.
EAU shares many features of clinical uveitis. Data presented
here that IL-33 plays an endogenous tissue protective role in EAU
and IL-33 administration ameliorates EAU, suggest that IL-33 may
be a potential option for treating clinical uveitis.
Materials and methods
Mice and reagents
C57BL/6 and BALB/c mice were purchased from Harlan (UK)
and maintained at the Biological Procedure Unit, University of
Strathclyde and University of Aberdeen. ST2−/− mice on C57BL/6
background were described previously [20]. ST2−/− and the WT
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littermates were maintained in the animal facilities of Glasgow
University. All experiments were performed under the guidelines
of the UK Home Office Animals (Scientific Procedures) Act 1986
and to the Association for Research in Vision and Ophthalmol-
ogy Statement for the Use of Animals in Ophthalmic and Vision
Research. Female mice (7–12 weeks old) were used in all exper-
iments. Murine recombinant IL-33 was obtained from BioLegend
(UK).
RPE cell culture and qPCR
RPE cell line (B6-RPE07) was derived from a 12-week-old na¨ıve
female C57BL/6 mouse and generated as described previously
[28]. Cells were cultured in T75 flasks in complete DMEM con-
taining 10% (v/v) fetal calf serum (Sigma) and incubated in
5% CO2 at 37°C. Seventy percent confluent cells were detached
from flasks using 0.25% trypsin-EDTA and cultured in 24-well
plates with different concentrations of IL-33 (10–100 ng/mL) or
LPS (100 ng/mL, Sigma) for 24 h. Cells were then collected and
lysed with RNA lysis buffer (Ambion, Life Technologies) for anal-
ysis of Il33 and Mcp-1 mRNA expression using Fast SYBR R© Green
real time PCR.
EAU induction and clinical evaluation
EAU was induced as described previously [3]. In brief, WT or
ST2−/− C57BL/6 mice were immunized subcutaneously on the
lower back with 300 mg of IRBP1–20 peptide (Sigma Genosys) in
50 µL of PBS emulsified with an equal volume of CFA (4 mg/mL
Mycobacterium tuberculosis, strain H37RA, Difco, Detroit MI). Each
mouse also received i.p. 500 ng/200 mL of pertussis toxin (PTX,
Sigma) in PBS. To investigate the effect of IL-33 on EAU devel-
opment, WT mice were injected i.p. every other day with IL-33
(0.5 µg/100 µL) from day 9 to 25 after the initial immuniza-
tion. Control WT mice received the same volume of PBS. Clinical
evaluation of ocular inflammation was performed using the fun-
dus imaging system as previously described [46]. Briefly, mice
were anesthetized and pupils were dilated before taking images,
and viscoelastic material was used as medium for corneal surface
during imaging.
Histological evaluation of disease
Mice were euthanized in CO2 chamber and their eyes were
carefully removed and fixed in 2.5% (w/v) glutaraldehyde and
embedded in resin for standard H&E staining. In some experi-
ments, removed eyes were snap frozen in tissue freezing optimum
cutting temperature medium on dry ice for cryosectioning, H&E
or immunohistochemical staining.
Immunohistochemical staining
RPE cells were cultured in cell chambers and stained with anti-
IL-33 antibody (R&D Systems). Eye tissues of na¨ıve and EAU mice
(day 16 after immunization) were frozen in optimum cutting tem-
perature and 8 µm sections were stained with anti-IL-33 antibody,
followed by incubation with biotinylated secondary antibody
(Vector Laboratories) and detected with substrates (DAB or AMEC
from Vector Laboratories). For fluorescence staining, TRITC-
conjugated strepavidin was added to the tissues sections follow-
ing incubation with the secondary antibody. Fluorescence staining
sections were mounted with Vectashield containing DAPI (Vector
Laboratories). Isotypes with matching IgG (R&D Systems) were
used as negative controls.
DLN and spleen cell culture
DLN and spleen were collected and pooled within groups or
analyzed individually. Single-cell suspensions were cultured in
24-well plates at 4 × 106 cells/2 mL per well and stimulated
with medium alone or with 50 µg/mL of IRBP1–20 peptide. After
72 h, supernatants were collected and concentrations of selected
cytokines were measured by ELISA using paired antibodies
(eBioscience).
T-cell–EAU splenocyte co-culture
Mice were treated with five doses of IL-33 (0.5 µg/100 µL)
or PBS every second day. Spleen and LNs were harvested and
pooled within each group. Single-cell suspensions were collected
and CD4+ T cells were purified using CD4+ T-cell isolation kit II
(Miltenyi Biotec, UK). Purified T cells (1 × 106) were co-cultured
(in 24-well pates, 2 mL per well) with 2 × 106 spenocytes of day
18 EAU mice in the presence of 50 µg/mL IRBP peptide. After
72 h, supernatants were harvested for IL-17 ELISA.
Flow cytometry analysis
Antibodies were purchased from BD Pharmingen unless
mentioned otherwise. RPE cells were harvested and washed before
staining with anti-IL-33 (R&D System) or ST2 (MD Biosciences)
antibodies. To examine the leukocyte phenotype in the DLN and
spleen, single-cell suspensions were stained with anti-F4/80, anti-
CD206 (MR, Serotec) and anti-CD273 (PD-L2, eBioscience) anti-
bodies. For measurement of intracellular cytokines, cells were
restimulated with 50 ng/mL phorbol-12-myristate-13-acetate and
500 ng/mL ionomycin (both from Sigma) in the presence of Golgi-
Stop (BD Bioscience) for 4 h. Cells were then harvested and
stained with cell surface anti-CD4 antibody before being perme-
abilized with Perm/Fix solution (eBioscience) and finally stained
with anti-IL-17A (clone eBio17B7), anti-IFN-γ (clone XMG1.2),
anti-IL-5 (TRFK4), and anti-IL-4 (clone 11B11) antibodies
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(eBioscience). Isotype-matched IgG antibodies from eBioscience
were used as negative controls. Cells were analyzed by FACS Cal-
ibur using CellQuest software (BD Biosciences).
Statistical analysis
Statistical evaluations of cell frequency, cytokine production, and
histological analysis were performed with the two-tail unpaired
Student’s t-test or Mann–Whitney test. p < 0.05 was considered
statistically significant. All experiments were repeated at least
twice.
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